The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year of treatment Safety profile remains unchanged and is aligned with the safety findings in the AURORA clinical program…